Trials / Completed
CompletedNCT01557127
Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 205 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid) |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2014-05-16
- Completion
- 2016-03-31
- First posted
- 2012-03-19
- Last updated
- 2017-03-28
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT01557127. Inclusion in this directory is not an endorsement.